MedPath
NMPA Approval

Rivastigmine Hydrogen Tartrate Capsules

国药准字HJ20181098

May 13, 2022

H20181098

Drug Information

重酒石酸卡巴拉汀胶囊

瑞伐明

胶囊剂

3mg(以卡巴拉汀计)

化学药品

May 13, 2022

May 12, 2027

Company Information

Applicant Company

Survey No. 1012, Dadra-396193 U.T. of Dadra and Nagar Haveli and Daman and Diu, India

Manufacturing Company

Survey No. 1012, Dadra-396193 U.T. of Dadra and Nagar Haveli and Daman and Diu, India

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

重酒石酸卡巴拉汀胶囊 - NMPA 批准文号 | MedPath